ViroStatics

10 articles about ViroStatics

• ViroStatics AV-HALT Phase 2a Study in HIV/AIDS Paper Published in PLoS ONE

  10/22/2012

• ViroStatics CEO, Dr. Franco Lori, to Speak at the International Track During Pennsylvania Biotech 2011

  10/24/2011

• ViroStatics CEO, Franco Lori, MD, Presents Late Breaker on Novel AV-HALT HIV Therapy at the 2011 International AIDS Society Pathogenesis Conference

  7/20/2011

• ViroStatics CEO Franco Lori, MD to Present Novel Immune-based Technologies for HIV/AIDS and Chronic Diseases at the 2011 Biotechnology Industry Organization (BIO) International Conference

  6/27/2011

• ViroStatics Demonstrates Clinical Proof of Concept for Dual Antiviral Anti-Hyperactivation AV-HALT Drugs

  3/2/2011

• Immunacia’s ViroStatics Reports Phase II Data on VS411, an AV-HALT for Treating HIV/AIDS, During the XVIII International AIDS Conference

  7/19/2010

• ViroStatics and Vichem Chemie Announce Strategic Partnership to Identify and Develop Kinase Inhibitors for the Treatment of HIV/AIDS and Other Chronic Diseases

  6/11/2010

• Dr. James Chafouleas Joins ViroStatics and Genetic Immunity as Strategic Adviser

  5/3/2010

• ViroStatics' Dr. Franco Lori to Present During 2009 Biotechnology Industry Organization (BIO) International Convention in Atlanta

  5/18/2009

• ViroStatics Acquires Library of Anti-Cancer/Antiviral Compounds From the University of Siena

  4/14/2009